RxTrials Institute Drug Pipeline Alert

Additional results of QuatRx Pharmaceuticals’ Phase III study of Ophena showed promise as a treatment for symptoms of vulvovaginal atrophy in postmenopausal women.

Results showed that, after 12 weeks of treatment, the mean scores for common clinical signs of vaginal atrophy were decreased by a statistically significant margin in groups treated with the drug as compared with placebo. Patients showed improvements in petechiae, pallor, friability, vaginal dryness and redness in mucosa, the company said.

The multicenter, double-blind, placebo-controlled study was conducted at 80 U.S. centers and involved 826 postmenopausal women. The drug was generally well tolerated.